Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Andrew BlauveltKristian ReichKim A PappA B KimballM GooderhamS K TyringR SinclairD ThaçiQ LiN CichanowitzS GreenC La RosaPublished in: The British journal of dermatology (2018)
Up to 64 weeks of tildrakizumab was well tolerated, with low rates of serious TEAEs, discontinuations due to AEs, and AEs of clinical interest.